CD3 high expression via M1 macrophages in Diabetic Patients treated with Metformin

Abstract

Abstract Introduction: Diabetes is categorized into types I and II, and the occurrence of type II is notably higher compared to type I. Type 2 diabetes is responsible for over 90% of patients with diabetes mellitus (DM). Immunometabolism researches have recently uncovered that Pancreas inflammation has been introduced as an important part of the type 2 diabetes pathogenesis and etiology and β-cell dysfunction in T2DM could be caused by a more intricate network of interactions between the various molecular pathways and environmental factors. The aim of this study is evaluated the CD3 expression via the M macrophages and proinflammatory cytokines in PBMC cells in Diabetic patients. Material and Methods The whole blood cells were taken from 40 diabetic patients with main criteria. The mononuclear cells were isolated via Trizol. The techniques which employed for present study are Real Time PCR, Immunoflorecanc, Flowcytometry and ELISA. Results The result of Treated cells with NTZ and metformin showed that the NTZ can enhanced the M0 and M2 expression with 20% deference from metformin. the macrophages in Metformin groups secreted higher levels of IL-1 and IL-6 on 24 hours after treated. The results showed that the CD3 expression was increased in metformin group compare with NTZ group. Conclusion Present study concluded that the metformin can increase the CD3 expression in diabetic patients via the enhancing of M1 expression and proinflammatory cytokines. In addition NTZ can increase the M2 expression in 24 hours after treating the cells but don’t have ability to increase the proinflammatory cytokines expression like Metformin.